What Degram Treats: Main Uses and Benefits

Degram (Nalidixic Acid) is commonly used for the management of acute bacterial infections confined to the lower urinary tract. As such, the medication is relevant in addressing infections caused by susceptible Gram-negative microorganisms, such as E. coli, which are commonly linked to these infections. The drug is applicable within clinical settings that involve acute or disruptive symptom patterns, playing a role in managing the infection and associated discomfort.

Its therapeutic support is applied in addressing the symptoms related to physical discomfort that characterize an active lower UTI. This includes dysuria (pain or burning during urination) and the disruptive feelings of urinary urgency and frequency. By addressing the bacterial presence, the medicine contributes to easing the overall symptom load and supports patients during difficult episodes. The medication is commonly used to help with conditions characterized by periods of heightened symptoms, supporting the patient during difficult episodes and assisting with maintaining functional stability.

---

Quick Fact: Relief for Urinary Discomfort Degram is primarily used to manage acute lower UTIs caused by susceptible bacteria, which may assist in easing the associated symptoms of painful urination and disruptive urinary urgency and frequency.

Regulatory References

1. NIH DailyMed label context

Who can and cannot use Degram?

Eligibility to use Degram (Nalidixic Acid) is strictly defined by official regulatory documents based on age, existing health conditions, and physiological status. The medicine is approved for use in adults and pediatric patients aged three months and older.

Populations Prohibited or Restricted by Labeling

Absolute Contraindications (Must Not Use)	Conditional Use Restrictions (Caution Required)
Infants younger than three months of age	Severe Renal or Hepatic Impairment
Known Hypersensitivity to nalidixic acid	Known or suspected Central Nervous System (CNS) disorders, such as epilepsy or severe cerebral arteriosclerosis
History of Convulsive Disorders	Patients with G6PD deficiency
Porphyria	Older adults (due to increased likelihood of decreased renal function)
Concomitant use with melphalan or related alkylating agents	Prepubertal children (use with caution)

Use is formally contraindicated during lactation according to the manufacturer's label. For pregnancy, the medicine is assigned FDA Pregnancy Category C, meaning its use is conditionally permitted only when the potential benefit is determined to outweigh the risk.

Degram (Nalidixic Acid) has officially documented interaction patterns that establish constraints for co-administration based on pharmacokinetic and pharmacodynamic effects, as described in regulatory documents.

Interaction Restrictions and Classifications

Co-administration with Melphalan and other related cancer chemotherapeutic alkylating agents is contraindicated due to the official risk of serious gastrointestinal toxicity. The risk of tendon effects (e.g., rupture) is officially stated to be increased when Degram is used alongside Corticosteroids, a concern heightened specifically in the elderly population.

Exposure and Clearance Alterations

Nalidixic Acid alters the exposure of certain co-administered medicines. The clearance of Theophylline is decreased, leading to increased plasma concentrations. Additionally, the effect of Oral Anticoagulants like Warfarin is officially noted to be increased, resulting in excessive anticoagulation. The regulatory label also notes that co-administration with Caffeine may increase the substance's effects.

Administration-Timing Constraints

A primary pharmacokinetic interaction involves decreased absorption. Products containing polyvalent cations, such as Antacids (magnesium, aluminum), Sucralfate, Iron, and Zinc (in multivitamins), significantly decrease the absorption of Nalidixic Acid. To prevent this reduction in exposure, these cation-containing agents must not be taken within the two-hour period before or within the two-hour period after Degram administration.

Target-Specific Poisoning of Bacterial DNA Gyrase

The drug exerts its effect by acting as a highly specific enzyme inhibitor, primarily targeting Bacterial DNA Gyrase ( Topoisomerase II), and to a lesser extent, Topoisomerase IV. These are enzymes involved in regulating the supercoiling of the bacteria's genetic material. The drug is classified as a topoisomerase poison because it stabilizes the temporary complex formed when the enzyme cleaves the bacterial DNA strands. This specialized action prevents the crucial final step of DNA religation, locking the enzyme onto the DNA.

The Bactericidal Cascade and Genome Fragmentation

This molecular interference initiates a rapid mechanistic cascade within the bacterial cell. By blocking the resealing of DNA strands, the drug ensures the accumulation of irreversible double-strand DNA breaks (DSBs), particularly when the bacteria attempt to replicate. This overwhelming genetic damage triggers the bacterial stress response, which ultimately fails to repair the extensive lesions. The physiological consequence of this targeted genetic disruption is the destruction and lysis of the susceptible microbial cell population (bactericidal action).

Mechanistic Constraints

The drug’s action is limited by intrinsic and acquired factors. Resistance can arise through target modification, where gene mutations (e.g., in gyrA) structurally alter the DNA Gyrase enzyme, reducing the drug’s binding affinity and diminishing its ability to induce DNA breaks. Furthermore, the mechanistic effect is intrinsically more pronounced when bacteria are actively replicating.

Degram (Nalidixic Acid) is administered exclusively via the oral route, available as both a tablet and an oral suspension. The general principle for its use involves a standardized four-times-daily (q.i.d.) schedule.

---

Standard Regimens and Duration

Initial adult therapy requires a dose of 1 g per administration, totaling 4 g daily. This initial dose is typically maintained for the course of initial treatment, which is 7 to 14 days. For any required prolonged therapy, the total daily dose is reduced to 2 g (500 mg four times daily). Underdosing the initial course (less than 4 g daily for adults) is a key administration concern, which may predispose to the emergence of bacterial resistance.

---

Administration Conditions and Adjustments

The medicine may be taken with or without meals. Patients are advised to maintain liberal fluid intake during the course of use. A specific administration constraint exists regarding co-ingestion: Degram must not be taken within the two-hour window before or after taking certain cation-containing products such as antacids (magnesium, calcium, aluminum), iron supplements, or sucralfate, due to potential interference with the drug’s absorption.

Regarding patient-specific modifications, the medication is not administered to pediatric patients younger than three months of age. Furthermore, in adult patients with severe renal impairment (creatinine clearance CrCl le 20 mL/min), the standard dose must be halved.

Research evidence / Overview of Studies for Degram

Evidence for Use in Acute Lower Urinary Tract Infections

Nalidixic Acid was studied in earlier clinical trials, including Randomized Controlled Trials (RCTs), exploring its use for acute, uncomplicated lower urinary tract infections (UTIs). These studies typically focused on populations of adult women with infections caused by susceptible Gram-negative bacteria, such as E. coli.

Researchers monitored two key outcomes: bacteriological clearance, which measures the eradication of the targeted bacteria from the urine, and clinical success, which monitors how patient-reported urinary symptoms evolved during the study period. Early findings from this research describe patterns related to the measurements of bacteriological clearance and patient-reported symptoms in the observed populations.

Research provides insight into the short-term changes measured during treatment; however, long-term outcomes are not fully established. Data concerning the drug's utility against modern bacterial strains are still limited, as evidence quality varies across the decades of research. Many older trials were conducted before the widespread emergence of contemporary antibiotic resistance patterns.

---

Studies on Long-Term Outcomes and Recurrence

Research has explored the changes associated with Nalidixic Acid that extend beyond the immediate treatment period, specifically by monitoring patients for a few weeks or months post-therapy. Studies have examined the infection recurrence rate, which describes patterns of recurrence in the observed population after the initial treatment course was finished.

Findings in this area describe patterns of recurrence, with some studies monitoring patients for up to five months or more to observe the sustained status of bacteriological and clinical measurements. However, long-term outcomes are not fully established, and follow-up durations were limited in many of the available research protocols.

---

Evidence in Specific Patient Populations

Studies have evaluated the use of Nalidixic Acid in specific patient groups, including pediatric patients (children over three months of age) with UTIs. Some research explicitly monitored for outcomes related to growth or joints, which are recognized areas of concern for the quinolone class of antibiotics.

Research indicates that the use of this drug class in children is restricted, based on safety concerns identified in studies related to other quinolones. Consequently, research findings for this group are limited. Data for certain complex patient groups or patients with underlying conditions remain insufficient for drawing broad conclusions, and the research available is often historical.

---

Evidence Gaps and Regulatory Limitations

The evidence landscape includes official regulatory reviews of Nalidixic Acid and the broader quinolone class. The European Medicines Agency (EMA), for example, determined that the marketing authorization for drugs containing Nalidixic Acid should be suspended, following a regulatory review of the drug class’s benefit-risk profile.

These regulatory decisions were based on official reviews of available data, including post-marketing data, regarding the drug's profile when used for certain infections like uncomplicated UTIs. Research describes patterns showing that the utility of this agent is limited by the emergence of bacterial resistance—a pattern noted across multiple studies. Therefore, the evidence indicates that the drug's original findings must be considered alongside current limitations, including the varying evidence quality and the major regulatory restrictions placed on its use in certain geographic areas.

Key Studies & References

1. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics (EMA Regulatory Document)
2. Nalidixic acid and pivmecillinam for treatment of acute lower urinary tract infections (Randomized Controlled Trial)

Common questions about Degram (FAQ)

Q: How quickly should I expect to see an effect from Degram?

A: Official drug information indicates that after taking a dose, the highest levels of the active drug in the blood are generally reached in approximately one to two hours. This measurement, often called the peak plasma level, is typically when the drug's concentration is highest in the bloodstream.

---

Q: Is it true that Degram can make you feel sleepy?

A: Yes, regulatory documents list several central nervous system effects that have been reported with this medication. Among these effects, dizziness and drowsiness (somnolence) are officially documented as possible adverse reactions.

---

Q: Will Degram interact with my regular vitamins or supplements?

A: Regulatory documents state that certain products can interfere with the absorption of the drug. Specifically, products containing polyvalent cations such as iron and zinc (found in many vitamins and supplements) may decrease how much of the drug is absorbed if taken too close together. Official guidelines recommend a separation in administration time for these substances.

---

Q: Why do official documents mention Degram's half-life?

A: The term half-life describes the time it takes for the amount of the drug in the blood to decrease by half. Official documents report that the half-life for the active drug in the plasma is short, typically ranging from 90 minutes to 2.5 hours in individuals with normal kidney function. This measurement provides insight into how the medicine is cleared from the body.

---

Q: Is Degram available as a generic medication?

A: Yes, the active ingredient in this medication is Nalidixic Acid. This is the non-proprietary or generic name for the substance, and it is available under this name, as well as under various brand names.

---

Q: Why is the information in the patient leaflet so complicated?

A: Official patient leaflets and prescribing information are legally required by regulatory bodies to disclose a comprehensive and detailed account of the drug's profile. This includes every documented safety risk, efficacy finding, and complex medical detail, which ensures full transparency for healthcare providers and patients alike.

---

Q: How long does Degram stay in the system after the last dose?

A: Official information describes the drug's elimination based on a short plasma half-life of 90 minutes to 2.5 hours. However, the drug and its active breakdown products are primarily cleared from the body through the urine over a longer duration.

---

Q: Can Degram be taken long-term?

A: Official regulatory documents define a lower dosage regimen for use in prolonged therapy following the initial course of treatment. The official documentation indicates that when treatment duration exceeds two weeks, periodic monitoring of blood counts and organ function tests is warranted.

---

Q: What happens if a dose of Degram is missed?

A: According to official patient instructions, if a dose is missed, it is described as being taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the regulatory guidance states that the missed dose should be skipped entirely in favor of the next scheduled dose.

---

Q: Is Degram considered a controlled substance?

A: No, the active ingredient, Nalidixic Acid, is not categorized as a controlled substance. It is not listed in any schedule under the US Controlled Substances Act (CSA) or similar international frameworks.

---

Q: Does the time of day matter when taking Degram?

A: The official administration instructions require that the medication be taken four times daily (q.i.d.). The purpose of this schedule is to help keep the concentration of the drug consistent throughout the treatment period.

---

Q: Are there different strengths of Degram available?

A: Yes, official regulatory documents indicate that the drug is available in several strengths for tablets, such as 250 mg, 500 mg, and 1 g forms. It is also available as a liquid oral suspension, which contains 250 mg per 5 mL.

---

Q: Is it possible to take Degram while pregnant or breastfeeding?

A: The drug is assigned FDA Pregnancy Category C and its use is conditionally permitted during pregnancy when the potential benefit is determined to outweigh the risk to the fetus. Furthermore, official product information states that its use is contraindicated (prohibited) during lactation (breastfeeding).

---

Q: Can Degram be crushed or cut in half?

A: Official patient instructions generally recommend that tablets be swallowed whole. Unless a manufacturer specifically states that a tablet can be altered, this practice is generally described as potentially affecting how the medicine is absorbed by the body.

---

Q: Is there a known risk of dependence with Degram?

A: The official regulatory labeling for this drug does not include a section on Drug Abuse and Dependence. There are no reported patterns of physical or psychological dependence associated with its use documented in the official product information.

---

Q: Can Degram be stopped suddenly, or does the dose need to be reduced?

A: Official instructions state that treatment should be completed for the full prescribed time, even if symptoms improve quickly. The full course is necessary to address the infection.

---

Q: Does Degram affect fertility?

A: Regulatory documents contain data from nonclinical toxicology studies that have been conducted to evaluate potential effects on fertility. These findings, based on animal studies, are described in the official product information.

---

Q: Is there a risk of interaction with cold and flu medicines?

A: The regulatory documents list specific drugs and substance classes known to interact with this medication. Official interaction lists should be reviewed because these common remedies can sometimes contain substances, such as polyvalent cations, which are known to interact with the drug.

The storage and disposal of Degram (Nalidixic Acid) must strictly follow official regulatory guidelines to maintain product stability and ensure safety.

Official Storage Conditions

Requirement	Detail based on Regulatory Labeling
Temperature	Store at Controlled Room Temperature (CRT), typically 20 C to 25 C.
Protection	Store in a dry place and keep the container tightly closed to protect against moisture.
Freezing	Do not freeze the oral suspension form.

Stability and Disposal Rules

Requirement	Detail based on Regulatory Labeling
Suspension Life	Any reconstituted oral suspension must be discarded after 14 days of preparation.
Child Safety	Keep this and all medicine out of the reach of children.
Disposal	Dispose of unused or expired medicine according to local requirements. Do not flush down the toilet unless officially instructed.

These official statements define how Degram must be stored and protected from environmental factors, including temperature and moisture, and outline the mandatory procedure for its safe disposal.